Status:
COMPLETED
Prediction Model of Microvascular Ischemic Ocular Motor Nerve Palsy and Inflammatory Ocular Motor Nerve Palsy in Chinese Patients
Lead Sponsor:
Beijing Tongren Hospital
Conditions:
Neuro-Ophthalmology
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to train and validate deep learning systems (DLS) to differentiate between microvascular ischemic ocular motor nerve palsy (v-OMNP) and inflammatory ocular motor nerve palsy (i-OMNP)....
Eligibility Criteria
Inclusion
- The diagnosis of disease is the outcome of the study. The inclusion criteria and exclusion criteria were as follows:
- Patients with acute bilateral diplopia within 1 week of onset at admission.
- 1\. Ischemic Group:
- Sudden onset of unilateral CN III, CN IV, or CN VI palsy.
- Isolated CN III (without pupil involvement), CN IV, or CN VI palsy.
- Presence of vascular risk factors (VRFs).
- Significant symptom recovery no earlier than 2 months after onset, with complete (or nearly complete) recovery within 3-6 months.
- 2\. Inflammatory Group:
- Unilateral painful CN III, CN IV, and/or CN VI palsy.
- Symptoms (including pain or diplopia signs) significantly improved within 72 hours after treatment with corticosteroids.
- MRI of the cavernous sinus showing inflammation, i.e., abnormal widening/enhancement of the affected cavernous sinus with or without granulomatous changes/inflammatory manifestations of adjacent tissues.
Exclusion
- 1\. Ocular muscle palsy confirmed to be caused by tumors, trauma, infections, stroke, carotid-cavernous fistula, aneurysms, neuromuscular junction disorders, thyroid-related eye diseases, and hereditary diseases at onset or during follow-up.
- 2\. Presence of other neurological signs in addition to ocular muscle palsy. 3. Severe systemic diseases of the heart, liver, or kidneys, as well as psychiatric and mental illness.
- 4\. Pregnant or breastfeeding patients. 5. Patients who did not undergo gadolinium-enhanced MRI of the cavernous sinus. 6. Patients younger than 18 years at the time of enrollment. 7. Onset of symptoms more than 1 week before admission. 8. Incomplete data or follow-up period less than 6 months. 9. Disagreements in disease diagnosis.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
299 Patients enrolled
Trial Details
Trial ID
NCT06518096
Start Date
January 1 2020
End Date
April 30 2024
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongren Hospital
Beijing, Beijing Municipality, China, 102600